Swiss biotech developing multiplexed library preparation technologies for RNA sequencing (e.g., BRB-seq, DRUG-seq and 1536-well MERCURIUS DRUG-seq kits) to lower cost and increase throughput for large-scale transcriptomics in drug discovery and toxicology.
Investment Rounds
Capital activity and funding progression
| Amount | Date | Round |
|---|---|---|
| €9.9 M | Mar, 2026 | seed |
Industries
Frequently Asked Questions
Where is Alithea Genomics located?
Alithea Genomics is located in Lausanne, Switzerland.
What industries does Alithea Genomics operate in?
Alithea Genomics operates in the following industries: biotechnology, genomics, life sciences, drug discovery.
When was Alithea Genomics founded?
Alithea Genomics was founded on 2026-03-05.
How much total funding has Alithea Genomics raised?
Alithea Genomics has raised a total of $9,900,000.
Who are the investors in Alithea Genomics?
The investors in Alithea Genomics are: Novalis Biotech, Genku Ventures, Several private investors.
What is the primary focus of Alithea Genomics?
Alithea Genomics specializes in providing high-throughput and cost-effective solutions for RNA sequencing, particularly through their proprietary bulk RNA barcoding technologies.
What is the Alithea Genomics MERCURIUS BRB-seq technology?
MERCURIUS BRB-seq is a specialized library preparation method that allows for the multiplexing of many samples into a single tube, significantly reducing the cost and time required for large-scale transcriptomics projects.
How does Alithea Genomics support drug discovery?
Through their DRUG-seq platform, the company enables high-throughput transcriptomics directly from cell lysates, bypassing expensive RNA purification steps and facilitating large-scale compound screening.
What are the benefits of using Alithea Genomics kits?
The kits offer a streamlined workflow that reduces plastic waste, minimizes hands-on time, and provides high-quality data at a fraction of the cost of traditional library preparation methods.
Can Alithea Genomics technology be used with biobanks?
Yes, their technologies are designed to handle large sample cohorts efficiently, making them ideal for biobanking applications where high-volume RNA analysis is required for biomarker discovery and clinical research.